Biomea Fusion, Inc. (BMEA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09077A1060
Biomea Fusion, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -83.51 m USD |
| EBIT | -61.80 m USD |
| Net income | -61.80 m USD |
| Diluted EPS – continuing operations | -1.18 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
More stocks
- Wiable Corp (065530.KQ)
- Pan Global Resources Inc (PGZ.V)
- XBP Global Holdings, Inc. (XBP)
- Elicio Therapeutics, Inc. (ELTX)
- Dogwood Therapeutics, Inc. (DWTX)
- Lithium Chile Inc (LITH.V)
- Joosung Corperation (109070.KS)
- Jericho Oil Corp (JEV.V)
- Ene Technology Inc (6243.TW)
- Foxwell Power Co., Ltd. (6994.TW)
- 2INVEST AG NA O.N. (2INV.F)
- CATO CORP (CATO)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.